NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Vizgen

Vizgen

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://vizgen.com/

Last Round

Series E

Jan 8, 2026

Total Funding Raised

$328.7M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Vizgen is a biotechnology company that provides spatially resolved, single-cell gene expression profiling tools to enhance understanding of biological systems and diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Biotech Equipment, Medical Imaging, Precision Medicine, Drug Discovery

Business Model

B2B

Customer Profile

Usage-Based SaaS, Hardware Sales, Services & Consulting, Government Contracts

AI Layer

Application

Keywords

spatial genomicsspatial transcriptomicsMERSCOPE PlatformMERFISHsingle-cell analysisspatial biologylife science toolsgene expression analysisspatial multi-omicstissue imagingin-situ hybridizationspatial proteomicssubcellular resolutionspatial bioMultiplexed Error-Robust Fluorescence In Situ Hybridizationscientific instrumentsresearch consumablesgene panels

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Vizgen Comps

Public and private peers based on sector, stage, and business model.

Vizgen comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Vizgen Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series EJan 8, 2026
Series DOct 9, 2024
Growth EquityMar 8, 2024
Series CJun 3, 2022
Series BJul 20, 2021
Series B
Apr 7, 2021

Key People

Founding team and executive leadership

Rob Carson

President CEO, Board Director

Executive Team

Chris Guiffre

Interim CFO

Executive Team

Vizgen Investors

Notable investors and investment history

Vizgen investors
InvestorRounds
SofinaSeries C
ARCH Venture PartnersSeries B, Series D, Series C, Series A, Series E
M VenturesSeries D, Series E
Northpond VenturesSeries C, Series D, Series B, Series A, Series E
ARCH Venture PartnersSeries B, Series D, Series C, Series A, Series E
Sofina S.A.Series C
Blue Water Life Science AdvisorsSeries C

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 8, 2026

    $48M Series E round completed.

  • Nov 17, 2025

    Collaboration with Ultivue to serve big pharma customers and CROs.

Vizgen Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Vizgen Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Vizgen's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range156
Year Founded2019
Last FundingJan 8, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.